Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | ACR | P10323 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127866 | 0.81 | ESR1 (0.51) | NPC1RAB9AKMT2ANOS3HTR3E | |
| SCHEMBL5423613 | 0.78 | NOS3 (0.68) | NPC1RAB9AKMT2ANOS3HTR3E | |
| SCHEMBL23864974 | 0.77 | KDM4E (0.56) | PTGS2RAB9AKDM4EKMT2AHPGD | |
| SCHEMBL15322353 | 0.73 | KDM4E (0.51) | NPC1RAB9AKDM4EKMT2ANOS3 | |
| SCHEMBL15322356 | 0.73 | KDM4E (0.51) | NPC1RAB9AKDM4EKMT2ANOS3 | |
| SCHEMBL4517019 | 0.72 | RAB9A (0.55) | NPC1RAB9AKMT2ANOS3HTR3E | |
| SCHEMBL16373407 | 0.72 | HPGD (0.56) | PTGS2NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL5425354 | 0.71 | RAB9A (0.61) | NPC1RAB9AKMT2ANOS3HTR3E | |
| SCHEMBL17396258 | 0.70 | NOS3 (0.49) | NPC1RAB9ANOS3HTR3EHTR3B | |
| SCHEMBL11769989 | 0.70 | CYP2D6 (0.66) | NPC1RAB9AKDM4EKMT2ANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423149-B2 | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1706375-A2 | SUBSTITUTED N-ARYL AMIDINES AS SELECTIVE D1 DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS | SCHERING CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063697-A2 | SUBSTITUTED N-ARYL AMIDINES AS SELECTIVE D1 DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS | SCHERING CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137210-A1 | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137210-A1 | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | GPR119, GLP1R, DRD1 | PTGS2 4687/4885NPC1 909/4885RAB9A 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.